Soon after, the FDA and Health Canada expanded the approved use of originator trastuzumab for the treatment of early stage HER2+ breast cancer following the promising results of adjuvant breast cancer clinical trials [8, 9]. Here, ERBB2 is linked to breast carcinoma.